Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Rhea-AI Summary

Galectin Therapeutics (NASDAQ: GALT) has announced that the top-line results of their NAVIGATE trial, focusing on patients with MASH cirrhosis and portal hypertension, will be presented at the 2025 MASH-TAG Conference in Park City, Utah, from January 9-11, 2025.

The presentation, titled "Belapectin administered at 2mg/kg/LBW for 18 months reduced the incidence of varices development in patients with MASH cirrhosis and portal hypertension: Top line results from the NAVIGATE trial," will be delivered by Dr. Naim Alkhouri, Chief Medical Officer of Arizona Liver Health, on January 10, 2025, at 11:25 AM MST.

Additionally, the company's executive leadership will host one-on-one meetings in San Francisco during the JP Morgan Healthcare Conference from January 13-16, 2025, to discuss NAVIGATE topline results and future steps for the belapectin program with external stakeholders.

NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal hypertension will be presented during the 2025 MASH-TAG Conference, being held January 9-11, 2025 in Park City, Utah. Additionally, Company’s executive leadership will be hosting one-on-one meetings in San Franscico January 13-16, 2025, during JP Morgan Healthcare Conference and is looking forward to engaging external stakeholders on NAVIGATE topline results and discussing next steps for the belapectin program.

Presentation details

Title: Belapectin administered at 2mg/kg/LBW for 18 months reduced the incidence of varices development in patients with MASH cirrhosis and portal hypertension: Top line results from the NAVIGATE trial
Presenter: Naim Alkhouri, M.D., Chief Medical Officer, Arizona Liver Health, Chandler, AZ
Format: Oral presentation
Session: Deep Dive into Incretin and Endocrine Based Therapies
Date & Time: January 10, 2025 at 11:25 AM MST

About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.

Company Contact:

Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com

Investors Relations Contacts:
Kevin Gardner
kgardner@lifesciadvisors.com

Chris Calabrese
ccalabrese@lifesciadvisors.com

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin.

FAQ

What are the key findings of Galectin Therapeutics' NAVIGATE trial for MASH cirrhosis?

The NAVIGATE trial demonstrated that belapectin, administered at 2mg/kg/LBW for 18 months, reduced the incidence of varices development in patients with MASH cirrhosis and portal hypertension.

When and where will Galectin Therapeutics (GALT) present their NAVIGATE trial results?

Galectin Therapeutics will present the NAVIGATE trial results at the 2025 MASH-TAG Conference in Park City, Utah, on January 10, 2025, at 11:25 AM MST.

What is the dosage and duration of belapectin treatment in the NAVIGATE trial?

In the NAVIGATE trial, belapectin was administered at 2mg/kg/LBW (lean body weight) for a duration of 18 months.

Where will Galectin Therapeutics (GALT) hold investor meetings following the MASH-TAG presentation?

Galectin Therapeutics will hold one-on-one meetings in San Francisco during the JP Morgan Healthcare Conference from January 13-16, 2025.

Who will present the NAVIGATE trial results at the 2025 MASH-TAG Conference?

Dr. Naim Alkhouri, Chief Medical Officer of Arizona Liver Health, will present the NAVIGATE trial results.